Navigation Links
High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds
Date:12/2/2009

ANN ARBOR, Mich. Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it.

Researchers at the University of Michigan Comprehensive Cancer Center created a decision aid designed to inform women about the risks and benefits associated with tamoxifen, a drug that was first used to stop breast cancer from returning and has recently been shown to prevent breast cancer in the first place.

The U-M decision aid gave objective information about tamoxifen and was tailored to each woman's health history. The study targeted women who were at high risk of developing breast cancer within the next five years; 632 women participated.

"Tailored information is critical because the risks and benefits vary across women. This is one of the most detailed tailored decision aids to address breast cancer prevention. The information about the risks and benefits of tamoxifen was tailored to each woman's health history. That means, when women read this decision aid, they learned about how the drug was likely to affect them given their age, race, breast cancer history and medical history," says lead author Angela Fagerlin, Ph.D., associate professor of internal medicine at the U-M Medical School and a research investigator at the VA Ann Arbor Healthcare System.

After viewing the decision aid, 41 percent of women could correctly answer six questions about the risks and benefits of tamoxifen, while 63 percent correctly answered at least five of the six questions.

Despite this understanding, only 29 percent of women said they were likely to seek out more information about tamoxifen, and only 29 percent said they would ask their doctor about it. A scant 6 percent of women said they were likely to take tamoxifen.

Three months later, the researchers found that fewer than 1 percent of participants had started taking tamoxifen, and fewer than 6 percent had either talked to their doctor or sought more information.

Results of the study appear online in the journal Breast Cancer Research and Treatment.

"For any given woman, there is not a right or wrong answer in regards to whether she should take tamoxifen to prevent a first diagnosis of breast cancer. The goal of decision aids is to explain the risks and benefits in a clear way so that the woman is able to weigh these factors and make an informed decision about what is best for her," Fagerlin says.

While as many as 10 million women could be eligible to take tamoxifen to prevent breast cancer, few choose to do so.

Side effects were the biggest concern about tamoxifen cited in this study, with 80 percent of the participants worried about this. The side effects of tamoxifen include hormonal symptoms, including hot flashes, and sexual problems, as well as rare incidences of endometrial cancer, blood clots or cataracts.

"Experts have bemoaned the dearth of women taking these pills, worried that word has not gotten out about tamoxifen's ability to prevent breast cancer in high risk women. Our study shows that even when the word does get out, most women are too concerned about the pill's side effects to want to take it," says senior author Peter Ubel, M.D., professor of internal medicine and director of the Center for Behavioral and Decision Sciences in Medicine at U-M.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Mammograms May Boost Cancer Risk in High-Risk Women
2. Mammography may increase breast cancer risk in some high-risk women
3. Mammography May Increase Breast Cancer Risk in Some High-Risk Women
4. Should noninvasive ventilation be considered a high-risk procedure during an epidemic?
5. MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
6. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
7. NCCN Stresses Importance of PSA Testing in High-Risk Men
8. New drug for children with high-risk leukemia
9. Barriers to diabetes care include restaurants and high-risk lifestyles, says international review
10. Salt Boosts Blood Pressure in High-Risk Patients
11. Ovary Removal Lowers Odds of Cancer in High-Risk Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: